Skip to main content
. Author manuscript; available in PMC: 2020 Feb 19.
Published in final edited form as: Cell Rep. 2019 Feb 19;26(8):2009–2018.e6. doi: 10.1016/j.celrep.2019.01.089

Figure 4. ZrlA Is Required for Overcoming Antibiotic Exposure In Vitro and In Vivo.

Figure 4.

(A-D) WT and Δzr/A were grown (A) ± carbenicillin, (B) ± vancomycin, (C) ± polymyxin B, and (D) ± tetracycline with OD600 monitored overtime.

(E) WT and Δzr/A were grown in the presence of carbenicillin ± TPEN with OD600 monitored over time; data depict growth at 8 h relative to growth with no carbenicillin. ****p < 0.0001 as determined by one-way ANOVA with Tukey multiple comparison’s test from three independent experiments, means ± SD.

(F) WT and Δzr/A were grown in the presence of polymyxin B ± TPEN with OD600 monitored over time; data depict growth at 24 h relative to growth with no polymyxin B. ****p < 0.0001 as determined by one-way ANOVA with Tukey multiple comparisons test from three independent experiments, means ± SD.

(G) WT or Δzr/A bacterial burdens recovered from the lungs at 36 hpi. ***p < 0.001, ****p < 0.0001 as determined by Mann-Whitney U test; error bars are median ± interquartile range (n = 20).

(H) Competitive index ([input Δzr/A/WT])/[output Δzr/A/WT]) in the lungs at 36 hpi. ****p < 0.0001 as determined by Student’s t test with an arbitrary value of 1 or between treatments; error bars are median ± interquartile range (n = 20).

See also Figure S4.